Please try another search
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Name | Age | Since | Title |
---|---|---|---|
Luigi Naldini | 65 | - | Co-Founder & Chairman of the Executive Scientific Board |
Pierluigi Paracchi | 51 | 2014 | Vice Chairman of the Board, CEO & GM |
Bernard Rudolph Gentner | 49 | - | Co-Founder & Member of the Executive Scientific Board |
Jacopo Doveri | 51 | 2021 | Statutory Auditor |
Cesare Lazzaroni | 73 | 2021 | Statutory Auditor |
Kenneth C. Anderson | 73 | - | Member of Scientific Advisory Board |
Miriam Merad | - | 2021 | Member of Scientific Advisory Board |
Lisa M. Coussens | - | - | Member of Scientific Advisory Board |
Patrick Yung Wen | - | 2021 | Member of Scientific Advisory Board |
Carlo-Alberto Nicchio | 49 | 2021 | Chairman of the Board of Statutory Auditors |
Richard A. Flavell | 78 | 2021 | Member of Scientific Advisory Board |
Michele De Palma | - | - | Member of Scientific Advisory Board |
Wolf-Herve Fridman | - | 2021 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review